logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Arch Biopartners Inc.

ARCH.V

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for tā€¦ read more

Healthcare

Biotechnology

13 years

CAD

Exclusive to Premium users

Price

per share adjusted in CAD

$1.68

Price

-0.59%

-$0.01

$1.69

Previous Close

$1.70

Open

Premium

52w Discount
Market Cap

$111.059m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

-$361k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$3.029m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.05

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$4.260m

$533.530k

Assets

$4.794m

Liabilities

$2.827m

Debt
Debt to Assets

529.8%

-1.5x

Debt to EBITDA
Free Cash Flow

-$2.702m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in CAD.
No items found.
ā†‘ TopSummaryPriceFinancials
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.